Navigation Links
Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
Date:12/4/2008

t candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com. 

    Contacts:
    GendeLLindheim BioCom Partners
    Investors
    info@peregrineinc.com
    (800) 987-8256

    Media
    Barbara Lindheim
    (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
3. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
4. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
6. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
8. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
9. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
10. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
11. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Other Biology Technology:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 12Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 13Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function 2Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 2Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 4Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 5Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 6Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 7Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 8Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 9Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 10Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 12
Breaking Biology News(10 mins):White, but not pure 2White, but not pure 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 1Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 2Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 3Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 4Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 5Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 6Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 7Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 8CyberKnife Treatment for Medically Inoperable Lung Cancer 56512 1CyberKnife Treatment for Medically Inoperable Lung Cancer 56512 2Raleigh Comprehensive and Cosmetic Dentistry Announces Addition of New Practice to Raleigh Dentist Family 56508 1Raleigh Comprehensive and Cosmetic Dentistry Announces Addition of New Practice to Raleigh Dentist Family 56508 2